Please login to the form below

Not currently logged in
Email:
Password:

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

AstraZeneca's Medimmune subsidiary announced a collaboration this morning with UK company Immunocore that will focus on the development of cancer therapeutics.

The two companies will work on new drug based on Immunocore's Immune Mobilising Monoclonal T-Cell Receptor against Cancer (ImmTAC) technology, which encourages a patient's own immune system to tackle tumours.

The deal potentially covers a number of targets, with AZ offering an upfront fee of $20m and up to $300m in development and milestone payments per programme, plus royalties if any of the therapies reach the market.

Immunocore also has collaborations in place with GlaxoSmithKline and Roche/Genentech, as well as its own melanoma therapy in phase II testing.

Article by
Phil Taylor

9th January 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics